Follow The Filings

NAMS

Earnings company data as of 8:02 PM ET 10/22

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 4 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by NAMS's executives, directors and 10% owners in the last 12 months, from their Form 4s

All NAMS insider trades
  • $227K bought by 1 insider
  • $18.5M sold by 3 insiders outside a trading plan
  • $44.2M sold by 4 insiders under 10b5-1 plans
  1. Johannes Jacob Pieter Kastelein Chief Scientific Officer
    Planned sale
    $1.3M 50,246 shares at $25.03 42% of stake
    Traded Sep 30 Filed Oct 2
    ↗
  2. Michael H. Davidson CEO
    Buy
    $227K 10,000 shares at $22.65 +1.3% to stake
    Traded Sep 14 Filed Sep 15
    ↗
  3. Johannes Jacob Pieter Kastelein Chief Scientific Officer
    Planned sale
    $3.4M 125,000 shares at $26.91 64% of stake
    Traded Aug 24 Filed Aug 25
    ↗
  4. Louise Frederika Kooij Chief Accounting Officer
    Planned sale
    $3.2M 105,000 shares at $30.34 81% of stake
    Traded Jul 20 Filed Jul 22
    ↗
  5. Louise Frederika Kooij Chief Accounting Officer
    Planned sale
    $1.2M 40,000 shares at $30.20 62% of stake
    Traded Jun 22 Filed Jun 24
    ↗
  6. Louise Frederika Kooij Chief Accounting Officer
    Planned sale
    $2.3M 65,000 shares at $35.69 73% of stake
    Traded May 26 Filed May 27
    ↗
  7. Louis G Lange Director
    Sale
    $1.4M 44,619 shares at $30.42 81% of stake
    Traded Mar 11 Filed Mar 12
    ↗
  8. Louis G Lange Director
    Sale
    $829K 28,186 shares at $29.41 100% of stake
    Traded Mar 6 Filed Mar 10
    ↗
  9. Johannes Jacob Pieter Kastelein Chief Scientific Officer
    Planned sale
    $9.1M 300,000 shares at $30.30 81% of stake
    Traded Mar 5–9 Filed Mar 9
    ↗
  10. Michael H. Davidson CEO
    Sale
    $14.8M 443,707 shares at $33.25 72% of stake
    Traded Mar 2 Filed Mar 2
    ↗
  11. Michael H. Davidson CEO
    Planned sale
    $10.6M 306,293 shares at $34.53 64% of stake
    Traded Feb 24–26 Filed Feb 26
    ↗
  12. Johannes Jacob Pieter Kastelein Chief Scientific Officer
    Sale
    $1.6M 45,481 shares at $35.31 46% of stake
    Traded Feb 20 Filed Feb 24
    ↗
  13. Louise Frederika Kooij Chief Accounting Officer
    Planned sale
    $2.3M 72,428 shares at $32.25 75% of stake
    Traded Jan 27–28 Filed Jan 29
    ↗
  14. Louise Frederika Kooij Chief Accounting Officer
    Planned sale
    $2.4M 72,572 shares at $33.29 75% of stake
    Traded Jan 23–26 Filed Jan 27
    ↗
  15. Mayur Ian Somaiya CFO
    Planned sale
    $3.3M 100,000 shares at $32.61 63% of stake
    Traded Jan 20–21 Filed Jan 22
    ↗

Also filed in the last 12 months, not counted as buying or selling: 26 option exercises, 11 stock grants, and 5 sales to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 23 shown.

Filed Form Detail Links
8-K 8.01,9.01 Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 8.01 Filing Doc
8-K 5.02 Filing Doc
8-K/A 5.02 Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 5.02 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
SCHEDULE 13D/A — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
DEF 14A Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.